Current Perspectives on Gastric Cancer

Gastroenterology Clinics of North America

Volumn 45, Issue 3, 2016, Pages 413-428

  Marqués Lespier, Juan M ^a   González Pons, María ^b   Cruz Correa, Marcia ^b  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^b UNIVERSITY OF PUERTO RICO   (Puerto Rico)

Author keywords

Atrophic gastritis; Dysplasia; Gastric cancer; Helicobacter pylori; Intestinal metaplasia

Indexed keywords

ACETYLSALICYLIC ACID; ANTIOXIDANT; CAPECITABINE; CELECOXIB; CISPLATIN; FLUOROURACIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; RAMUCIRUMAB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CANCER SURVIVOR; CAUSE OF DEATH; CHEMOPROPHYLAXIS; DEMOGRAPHY; DIET SUPPLEMENTATION; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG TARGETING; ENDOSCOPIC MUCOSAL RESECTION; ENDOSCOPIC SUBMUCOSAL DISSECTION; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS; ERADICATION THERAPY; FAMILIAL CANCER; GASTRITIS; GASTROSCOPY; GENETIC PREDISPOSITION; HELICOBACTER INFECTION; HEREDITY; HISTOPATHOLOGY; HUMAN; INTESTINE METAPLASIA; LIFESTYLE MODIFICATION; NARROW BAND IMAGING; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; STOMACH CARCINOGENESIS; TOTAL STOMACH RESECTION; TUMOR LOCALIZATION; UNITED STATES; ADENOCARCINOMA; DIET; DRINKING BEHAVIOR; EPSTEIN-BARR VIRUS INFECTIONS; GASTRECTOMY; GASTRITIS, ATROPHIC; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; METAPLASIA; OBESITY; OCCUPATIONAL EXPOSURE; PATHOLOGY; SEX RATIO; SMOKING; STATISTICS AND NUMERICAL DATA; STOMACH NEOPLASMS;

ADENOCARCINOMA; ALCOHOL DRINKING; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DIET; EPSTEIN-BARR VIRUS INFECTIONS; GASTRECTOMY; GASTRITIS, ATROPHIC; GENETIC PREDISPOSITION TO DISEASE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METAPLASIA; OBESITY; OCCUPATIONAL EXPOSURE; RISK FACTORS; SEX DISTRIBUTION; SMOKING; STOMACH NEOPLASMS; TRASTUZUMAB;

EID: 84991270003     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2016.04.002     Document Type: Review

References (100)

1. 1 Kelley, J.R., Duggan, J.M., Gastric cancer epidemiology and risk factors. J Clin Epidemiol 56:1 (2003), 1–9.
2. 2 Ferlay, J., Soerjomataram, I., Dikshit, R., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:5 (2015), E359–E386.
3. 3 Ferlay, J., Shin, H.R., Bray, F., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:12 (2010), 2893–2917.
4. Soerjomataram, I., Lortet-Tieulent, J., Parkin, D.M., et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 380:9856 (2012), 1840–1850.
5. 5 Jemal, A., Bray, F., Center, M.M., et al. Global cancer statistics. CA Cancer J Clin 61:2 (2011), 69–90.
6. 6 Ferlay, J., Soerjomataram, I., Ervik, M., et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality Worldwide: IARC CancerBase No. 11 [Internet]. 2013, International Agency for Research on Cancer, Lyon (France) Available at: http://globocan.iarc.fr Accessed October 11, 2014.
7. 7 American Cancer Society, Cancer Facts & Figures 2016. 2016, American Cancer Society, Atlanta (GA).
8. 8 Correa, P., Gastric cancer: overview. Gastroenterol Clin North Am 42:2 (2013), 211–217.
9. 9 Noto, J.M., Peek, R.M. Jr., Helicobacter pylori: an overview. Methods Mol Biol 921 (2012), 7–10.
10. 10 Pounder, R.E., Ng, D., The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther 9:Suppl 2 (1995), 33–39.
11. 11 Correa, P., Cuello, C., Duque, E., Carcinoma and intestinal metaplasia of the stomach in Colombian migrants. J Natl Cancer Inst 44:2 (1970), 297–306.
12. 12 An international association between Helicobacter pylori infection and gastric cancer. The EUROGAST Study Group. Lancet 341:8857 (1993), 1359–1362.
13. 13 Figueiredo, C., Machado, J.C., Pharoah, P., et al. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst 94:22 (2002), 1680–1687.
14. 14 Bessede, E., Dubus, P., Megraud, F., et al. Helicobacter pylori infection and stem cells at the origin of gastric cancer. Oncogene 34:20 (2015), 2547–2555.
15. 15 Chen, X.Z., Chen, H., Castro, F.A., et al. Epstein-Barr virus infection and gastric cancer: a systematic review. Medicine (Baltimore), 94(20), 2015, e792.
16. 16 Murphy, G., Pfeiffer, R., Camargo, M.C., et al. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology 137:3 (2009), 824–833.
17. 17 Camargo, M.C., Kim, W.H., Chiaravalli, A.M., et al. Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis. Gut 63:2 (2014), 236–243.
18. 18 Han, M.A., Oh, M.G., Choi, I.J., et al. Association of family history with cancer recurrence and survival in patients with gastric cancer. J Clin Oncol 30:7 (2012), 701–708.
19. 19 Yaghoobi, M., Bijarchi, R., Narod, S.A., Family history and the risk of gastric cancer. Br J Cancer 102:2 (2010), 237–242.
20. 20 Figueiredo, C., Costa, S., Karameris, A., et al. Pathogenesis of gastric cancer. Helicobacter 20:Suppl 1 (2015), 30–35.
21. 21 Piazuelo, M.B., Correa, P., Gastric cancer: overview. Colomb Med (Cali) 44:3 (2013), 192–201.
22. 22 Oliveira, C., Pinheiro, H., Figueiredo, J., et al. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol 16:2 (2015), e60–70.
23. 23 Oliveira, C., Seruca, R., Carneiro, F., Genetics, pathology, and clinics of familial gastric cancer. Int J Surg Pathol 14:1 (2006), 21–33.
24. 24 Capelle, L.G., Van Grieken, N.C., Lingsma, H.F., et al. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology 138:2 (2010), 487–492.
25. Raj, A., Mayberry, J.F., Podas, T., Occupation and gastric cancer. Postgrad Med J 79:931 (2003), 252–258.
26. 26 Ladeiras-Lopes, R., Pereira, A.K., Nogueira, A., et al. Smoking and gastric cancer: systematic review and meta-analysis of cohort studies. Cancer Causes Control 19:7 (2008), 689–701.
27. 27 Gonzalez, C.A., Pera, G., Agudo, A., et al. Smoking and the risk of gastric cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). Int J Cancer 107:4 (2003), 629–634.
28. 28 Sinha, D.N., Abdulkader, R.S., Gupta, P.C., Smokeless tobacco-associated cancers: a systematic review and meta-analysis of Indian studies. Int J Cancer 138:6 (2016), 1368–1379.
29. 29 Leung, W.K., Lin, S.R., Ching, J.Y., et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 53:9 (2004), 1244–1249.
30. 30 Sjodahl, K., Lu, Y., Nilsen, T.I., et al. Smoking and alcohol drinking in relation to risk of gastric cancer: a population-based, prospective cohort study. Int J Cancer 120:1 (2007), 128–132.
31. 31 Abnet, C.C., Corley, D.A., Freedman, N.D., et al. Diet and upper gastrointestinal malignancies. Gastroenterology 148:6 (2015), 1234–1243.e4.
32. 32 D'Elia, L., Rossi, G., Ippolito, R., et al. Habitual salt intake and risk of gastric cancer: a meta-analysis of prospective studies. Clin Nutr 31:4 (2012), 489–498.
33. 33 Ge, S., Feng, X., Shen, L., et al. Association between habitual dietary salt intake and risk of gastric cancer: a systematic review of observational studies. Gastroenterol Res Pract, 2012, 2012, 808120.
34. 34 de Martel, C., Forman, D., Plummer, M., Gastric cancer: epidemiology and risk factors. Gastroenterol Clin North Am 42:2 (2013), 219–240.
35. 35 Peleteiro, B., Lopes, C., Figueiredo, C., et al. Salt intake and gastric cancer risk according to Helicobacter pylori infection, smoking, tumour site and histological type. Br J Cancer 104:1 (2011), 198–207.
36. 36 Zhu, H., Yang, X., Zhang, C., et al. Red and processed meat intake is associated with higher gastric cancer risk: a meta-analysis of epidemiological observational studies. PLoS One, 8(8), 2013, e70955.
37. 37 Gonzalez, C.A., Agudo, A., Carcinogenesis, prevention and early detection of gastric cancer: where we are and where we should go. Int J Cancer 130:4 (2012), 745–753.
38. 38 Chen, Y., Liu, L., Wang, X., et al. Body mass index and risk of gastric cancer: a meta-analysis of a population with more than ten million from 24 prospective studies. Cancer Epidemiol Biomarkers Prev 22:8 (2013), 1395–1408.
39. 39 Correa, P., Fontham, E.T., Bravo, J.C., et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 92:23 (2000), 1881–1888.
40. 40 Japanese Gastric Cancer Association, Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 14:2 (2011), 101–112.
41. 41 Botterweck, A.A., Schouten, L.J., Volovics, A., et al. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 29:4 (2000), 645–654.
42. 42 Henson, D.E., Dittus, C., Younes, M., et al. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type. Arch Pathol Lab Med 128:7 (2004), 765–770.
43. 43 Barber, M., Murrell, A., Ito, Y., et al. Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer. J Pathol 216:3 (2008), 295–306.
44. Washington, K., 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol 17:12 (2010), 3077–3079.
45. 45 Colquhoun, A., Arnold, M., Ferlay, J., et al. Global patterns of cardia and non-cardia gastric cancer incidence in 2012. Gut 64:12 (2015), 1881–1888.
46. 46 Lauren, P., The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64 (1965), 31–49.
47. 47 Correa, P., Cuello, C., Duque, E., et al. Gastric cancer in Colombia. III. Natural history of precursor lesions. J Natl Cancer Inst 57:5 (1976), 1027–1035.
48. 48 Kobayashi, M., Tsubono, Y., Sasazuki, S., et al. Vegetables, fruit and risk of gastric cancer in Japan: a 10-year follow-up of the JPHC Study Cohort I. Int J Cancer 102:1 (2002), 39–44.
49. 49 Plummer, M., Vivas, J., Lopez, G., et al. Chemoprevention of precancerous gastric lesions with antioxidant vitamin supplementation: a randomized trial in a high-risk population. J Natl Cancer Inst 99:2 (2007), 137–146.
50. 50 Song, J., Su, H., Zhou, Y.Y., et al. Cyclooxygenase-2 expression is associated with poor overall survival of patients with gastric cancer: a meta-analysis. Dig Dis Sci 59:2 (2014), 436–445.
51. 51 Wu, C.Y., Wu, M.S., Kuo, K.N., et al. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. J Clin Oncol 28:18 (2010), 2952–2957.
52. 52 Tian, W., Zhao, Y., Liu, S., et al. Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer. Eur J Cancer Prev 19:4 (2010), 288–298.
53. 53 Leung, W.K., Ng, E.K., Chan, F.K., et al. Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial. Clin Cancer Res 12:15 (2006), 4766–4772.
54. 54 Yanaoka, K., Oka, M., Yoshimura, N., et al. Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion. Int J Cancer 126:6 (2010), 1467–1473.
55. 55 Hung, K.H., Yang, H.B., Cheng, H.C., et al. Short-term celecoxib to regress long-term persistent gastric intestinal metaplasia after Helicobacter pylori eradication. J Gastroenterol Hepatol 25:1 (2010), 48–53.
56. 56 Singh, P.P., Singh, S., Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis. Ann Oncol 24:7 (2013), 1721–1730.
57. 57 Compare, D., Rocco, A., Nardone, G., Screening for and surveillance of gastric cancer. World J Gastroenterol 20:38 (2014), 13681–13691.
58. 58 Rokkas, T., Pistiolas, D., Sechopoulos, P., et al. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter 12:Suppl 2 (2007), 32–38.
59. 59 De Vries, A.C., Kuipers, E.J., Review article: Helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther 26:Suppl 2 (2007), 25–35.
60. 60 Wang, J., Xu, L., Shi, R., et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion 83:4 (2011), 253–260.
61. 61 Mera, R., Fontham, E.T., Bravo, L.E., et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut 54:11 (2005), 1536–1540.
62. 62 Uemura, N., Mukai, T., Okamoto, S., et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 6:8 (1997), 639–642.
63. You, W.C., Brown, L.M., Zhang, L., et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 98:14 (2006), 974–983.
64. 64 Fukase, K., Kato, M., Kikuchi, S., et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 372:9636 (2008), 392–397.
65. 65 de Vries, A.C., van Grieken, N.C., Looman, C.W., et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 134:4 (2008), 945–952.
66. 66 Lee, K.S., Oh, D.K., Han, M.A., et al. Gastric cancer screening in Korea: report on the national cancer screening program in 2008. Cancer Res Treat 43:2 (2011), 83–88.
67. 67 Jung, K.W., Won, Y.J., Kong, H.J., et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat 46:2 (2014), 109–123.
68. 68 Hamashima, C., Shibuya, D., Yamazaki, H., et al. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol 38:4 (2008), 259–267.
69. 69 Dinis-Ribeiro, M., Areia, M., de Vries, A.C., et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 44:1 (2012), 74–94.
70. 70 ASGE Standards of Practice Committee, Evans, J.A., Chandrasekhara, V., et al. The role of endoscopy in the management of premalignant and malignant conditions of the stomach. Gastrointest Endosc 82:1 (2015), 1–8.
71. 71 Rugge, M., Genta, R.M., Staging gastritis: an international proposal. Gastroenterology 129:5 (2005), 1807–1808.
72. 72 Capelle, L.G., de Vries, A.C., Haringsma, J., et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 71:7 (2010), 1150–1158.
73. 73 Satoh, K., Osawa, H., Yoshizawa, M., et al. Assessment of atrophic gastritis using the OLGA system. Helicobacter 13:3 (2008), 225–229.
74. 74 Rugge, M., de Boni, M., Pennelli, G., et al. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther 31:10 (2010), 1104–1111.
75. 75 Choi, I.J., Endoscopic gastric cancer screening and surveillance in high-risk groups. Clin Endosc 47:6 (2014), 497–503.
76. 76 Kluijt, I., Sijmons, R.H., Hoogerbrugge, N., et al. Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance. Fam Cancer 11:3 (2012), 363–369.
77. 77 Liu, W.Z., Xie, Y., Cheng, H., et al. Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection. J Dig Dis 14:5 (2013), 211–221.
78. 78 Asaka, M., Kato, M., Takahashi, S., et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 15:1 (2010), 1–20.
79. 79 The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc 58:6 Suppl (2003), S3–S43.
80. 80 Rey, J.F., Lambert, R., ESGE recommendations for quality control in gastrointestinal endoscopy: guidelines for image documentation in upper and lower GI endoscopy. Endoscopy 33:10 (2001), 901–903.
81. Omori, T., Kamiya, Y., Tahara, T., et al. Correlation between magnifying narrow band imaging and histopathology in gastric protruding/or polypoid lesions: a pilot feasibility trial. BMC Gastroenterol, 12, 2012, 17.
82. 82 Tanioka, Y., Yanai, H., Sakaguchi, E., Ultraslim endoscopy with flexible spectral imaging color enhancement for upper gastrointestinal neoplasms. World J Gastrointest Endosc 3:1 (2011), 11–15.
83. 83 Mouri, R., Yoshida, S., Tanaka, S., et al. Evaluation and validation of computed virtual chromoendoscopy in early gastric cancer. Gastrointest Endosc 69:6 (2009), 1052–1058.
84. 84 Jung, S.W., Lim, K.S., Lim, J.U., et al. Flexible spectral imaging color enhancement (FICE) is useful to discriminate among non-neoplastic lesion, adenoma, and cancer of stomach. Dig Dis Sci 56:10 (2011), 2879–2886.
85. 85 Pasechnikov, V., Chukov, S., Fedorov, E., et al. Gastric cancer: prevention, screening and early diagnosis. World J Gastroenterol 20:38 (2014), 13842–13862.
86. 86 Graham, D.Y., Schwartz, J.T., Cain, G.D., et al. Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma. Gastroenterology 82:2 (1982), 228–231.
87. 87 Waddell, T., Verheij, M., Allum, W., et al. Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol 40:5 (2014), 584–591.
88. 88 Ajani, J.A., D'Amico, T.A., Almhanna, K., et al. Gastric Cancer. NCCN clinical practice guidelines in Oncology (NCCN guidelines). 2015, National Comprehensive Cancer Network, Inc Version 3.2015. Available at: https://www.nccn.org/professionals/physician_gls/PDF/gastric.pdf Accessed February 10, 2016.
89. 89 Kantsevoy, S.V., Adler, D.G., Conway, J.D., et al. Endoscopic mucosal resection and endoscopic submucosal dissection. Gastrointest Endosc 68:1 (2008), 11–18.
90. 90 Kim, S.G., Endoscopic treatment for early gastric cancer. J Gastric Cancer 11:3 (2011), 146–154.
91. 91 Chung, I.K., Lee, J.H., Lee, S.H., et al. Therapeutic outcomes in 1000 cases of endoscopic submucosal dissection for early gastric neoplasms: Korean ESD Study Group multicenter study. Gastrointest Endosc 69:7 (2009), 1228–1235.
92. 92 Park, Y.M., Cho, E., Kang, H.Y., et al. The effectiveness and safety of endoscopic submucosal dissection compared with endoscopic mucosal resection for early gastric cancer: a systematic review and metaanalysis. Surg Endosc 25:8 (2011), 2666–2677.
93. 93 Blakely, A.M., Miner, T.J., Surgical considerations in the treatment of gastric cancer. Gastroenterol Clin North Am 42:2 (2013), 337–357.
94. 94 Hudis, C.A., Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med 357:1 (2007), 39–51.
95. 95 Bang, Y.J., Van Cutsem, E., Feyereislova, A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:9742 (2010), 687–697.
96. 96 Fuchs, C.S., Tomasek, J., Yong, C.J., et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:9911 (2014), 31–39.
97. 97 Siegel, R., Ma, J., Zou, Z., et al. Cancer statistics, 2014. CA Cancer J Clin 64:1 (2014), 9–29.
98. 98 Crew, K.D., Neugut, A.I., Epidemiology of gastric cancer. World J Gastroenterol 12:3 (2006), 354–362.
99. Surveillance, Epidemiology, and End Results (SEER) Program Research Data (1973-2010), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013, based on the November 2012 submission. Available at: www.seer.cancer.gov. Accessed January 26, 2016.
100. 100 Dassen, A.E., Lemmens, V.E., van de Poll-Franse, L.V., et al. Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands. Eur J Cancer 46:6 (2010), 1101–1110.